Browse by Poster Presenter

Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

T
Takaichi, Daisuke

Kyowa Kirin Co., Ltd
(W-120) Quantitative Systems Pharmacology Modeling of X-linked Hypophosphatemia Disease Pathway Normalization to Predict the Impact of Burosumab Treatment on Serum Biomarkers in Adult and Pediatric Patients
Daisuke Takaichi
Favorite
Takenaka, Misako

GlaxoSmithKline
(M-108) How should we leverage prior adult knowledge for pediatric PK analysis? - A case study comparing Pooled and Bayesian population PK approaches
Misako Takenaka
Favorite
Tang, Zoey

AstraZeneca
(W-122) Dual Target-Mediated Drug Disposition Model to Guide the Selection of Starting Dose and Escalation in FTIH Trials for Volrustomig (MEDI5752), a Monovalent Bispecific Antibody Targeting PD-1 and CTLA-4
Zoey Tang
Favorite
(W-123) Population pharmacokinetic analysis of Dato-DXd, a TROP2-targeting ADC, in NSCLC and HR-positive, HER2-negative breast cancer patients
Zoey Tang
Favorite
Tania, Nessy

Pfizer Research and Development
(M-109) Advancing Quantitative Systems Pharmacology Model for Inflammatory Bowel Disease for Clinical Efficacy Predictions in Ulcerative Colitis
Nessy Tania
Favorite
Tan, Wen Rui

Cincinnati Children's Hospital Medical Center
(W-121) Model-informed simulations to determine optimal Piperacillin-Tazobactam Dosing regimens in Pediatric Perioperative Care: Effect of body size and renal function
Wen Rui Tan
Favorite
Tao, Mengdi

Sanofi US
(T-115) Approaches for Developing a Robust Virtual Twin Workflow in Quantitative Systems Pharmacology Models
Mengdi Tao
Favorite
Tarek, Mohamed

Pumas-AI Inc., USA
(T-116) A DeepNLME-based Tumor Growth Dynamics and Overall Survival Model for Non Small Cell Lung Cancer
Mohamed Tarek
Favorite
Taylor, Adekemi

Certara Inc.
(M-137) A Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Model for Covalent Bruton Tyrosine Kinase Inhibitor TL-895
Adekemi Taylor
Favorite
Taylor, Zachary

Cincinnati Children's Hospital Medical Center
(T-117) A High-Dose Methotrexate Dashboard: Integrating MTXPK.org into the Electronic Health Record to Facilitate Model-Informed Care for Pediatric Patients with Malignant Conditions
Zachary Taylor
Favorite
Templeton, Ian

Certara; Simcyp Consultancy Division
(W-124) Real world examples of PBPK impact on CYP3A4 victim DDI drug label content
Ian Templeton
Favorite
Tendolkar, Amol

Bristol Myers Squibb
(T-118) Population Pharmacokinetic and Exposure-Response Analyses of Neoadjuvant Nivolumab plus Chemotherapy, followed by Adjuvant Treatment with Nivolumab in Subjects with Resectable Stage II-IIIB NSCLC
Amol Tendolkar
Favorite
THE UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER, Paridhi

Department of Pharmaceutical Sciences, University of Tennessee Health Science Center
(T-051) Mechanistic model-based analysis of Total IgG kinetics and pathogenic autoantibody pharmacodynamics in autoimmune diseases
Paridhi THE UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER
Favorite
(T-052) Modeling the Time-Varying Impact of Anti-Drug Antibody Formation on the Pharmacokinetics of a Human Monoclonal Antibody in a Preclinical Study
Paridhi THE UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER
Favorite
THIBAULT GREUGNY, Elea

Novadiscovery
(M-006) An innovative paradigm for non-small cell lung cancer clinical trial simulations through the Integration of a quantitative systemic pharmacology model and pharmacodynamic model of gemcitabine
Elea THIBAULT GREUGNY
Favorite
(M-007) Leveraging AI for improved reproducibility of mathematical disease models: insights from a retinitis pigmentosa case study
Elea THIBAULT GREUGNY
Favorite
Thomas, Haryana Yosef

University at Buffalo
(M-110) A quantitative systems pharmacology model for diabetes-induced glomerular fibrosis
Haryana Yosef Thomas
Favorite
tian, zhiteng

Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China
(T-119) Development of a Population Pharmacokinetic Model for Ganciclovir to Assess the Renal Impairment Impact in Chinese Patients
zhiteng tian
Favorite
Tobin, Kevin

Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD
(W-125) Flux-based IVIVC for predicting oxybutynin exposure with and without occlusion of a transdermal gel
Kevin Tobin
Favorite
(W-126) Population Pharmacokinetics of Atomoxetine at Steady-State Dosing for ADHD Treatment in Children and Adolescents
Kevin Tobin
Favorite
Tong, Dominic

InsightRX
(M-111) Cystatin C complements but does not exceed serum creatinine as a renal function marker: evidence from vancomycin pharmacokinetic model performance in a clinical context
Dominic Tong
Favorite
Tong, Xiao

Pharmacometrics, Quantitative Clinical Pharmacology & Biosimilars, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA
(W-127) Population pharmacokinetic and pharmacodynamic modeling of free serum interleukin-15 in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers.
Xiao Tong
Favorite
Toyoshima, Junko

Astellas Pharma Global Development, Inc.
(M-112) Evaluation of Praziquantel Exposures in Children Dosed Using Different Body Weight Estimation Methods
Junko Toyoshima
Favorite
Trame, Mirjam

Certara
(M-113) Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials
Mirjam Trame
Favorite
Tran, Brittany

Daiichi Sankyo, Inc.
(W-128) Population pharmacokinetics and exposure-safety of DS-6157a in patients with advanced gastrointestinal stromal tumor (GIST)
Brittany Tran
Favorite
Trogdon, Michael

Pfizer
(M-114) Virtual clinical trial simulations using a Quantitative Systems Pharmacology (QSP) model of CDK inhibitors in breast cancer patients
Michael Trogdon
Favorite
Tummala, Hari Prabhath

University of California, San Francisco
(T-120) Assessing Sirolimus and Antiretroviral Interactions in People with HIV on Chronic ART: A Population Pharmacokinetic Approach in Non-Transplant Recipients
Hari Prabhath Tummala
Favorite